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Abstract
Introduction: The NMDA receptor radiotracer [18F]GE-179 has been used with 90-min scans and arterial plasma
input functions. We explored whether (1) arterial blood sampling is avoidable and (2) shorter scans are feasible.
Methods: For 20 existing [18F]GE-179 datasets, we generated (1) standardised uptake values (SUVs) over eight
intervals; (2) volume of distribution (VT) images using population-based input functions (PBIFs), scaled using one
parent plasma sample; and (3) VT images using three shortened datasets, using the original parent plasma input
functions (ppIFs).
Results: Correlations with the original ppIF-derived 90-min VTs increased for later interval SUVs (maximal ρ = 0.78;
80–90 min). They were strong for PBIF-derived VTs (ρ = 0.90), but between-subject coefficient of variation increased.
Correlations were very strong for the 60/70/80-min original ppIF-derived VTs (ρ = 0.97–1.00), which suffered regionally
variant negative bias.
Conclusions: Where arterial blood sampling is available, reduction of scan duration to 60 min is feasible, but with
negative bias. The performance of SUVs was more consistent across participants than PBIF-derived VTs.
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Introduction
N-Methyl-D-aspartate (NMDA) receptors for L-glutam-
ate, the major excitatory neurotransmitter in the central
nervous system, are ligand- and voltage-gated ion chan-
nels [1]. Receptor activation is necessary for learning
while abnormal activation is associated with neurological
and psychiatric disease [1].
We reported the first-in-human use of the NMDA
receptor-selective PET radiotracer, [18F]GE-179 [2], an
analogue of the non-competitive antagonist, [11C]CNS-5161
[3]. Quantification of [18F]GE-179 volume of distribution
(VT) was based on 90-min scans and compartmental mod-
elling within regions of interest (ROIs) and using
rank-shaping regularisation of spectral analysis (SA) at the
voxel level. [18F]GE-179 binding in rats and non-human
primates could not be blocked in one recent study [4], but
interpretation is complicated by the use of anaesthesia with
the NMDA receptor inhibitors isoflurane [5] ± ketamine.
We have reported substantial global changes in [18F]GE-179
VT in patients with focal epilepsy, using “classical” SA [6],
which is more widely used than rank-shaping.
Several ongoing studies are using [18F]GE-179 PET. Wide
utilisation of [18F]GE-179 is limited by the need for arterial
blood sampling and 90-min scans. There is no suitable refer-
ence region devoid of NMDA receptors. To facilitate wide-
spread use, we report our investigations into (1) whether
arterial blood sampling is avoidable, via the use of standar-
dised uptake values (SUVs) or population-based input func-
tions (PBIFs) and (2) whether shorter scans are feasible.
Materials and methods
Data had been acquired previously after regulatory
approvals had been obtained [2, 6]. All participants pro-
vided written, informed consent prior to participation.
* Correspondence: colm.mcginnity@kcl.ac.uk
1Division of Brain Sciences, Imperial College London, London, UK
2MRC Clinical Sciences Centre, London, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
McGinnity et al. EJNMMI Research  (2018) 8:46 
https://doi.org/10.1186/s13550-018-0396-2
Arterial blood and dynamic [18F]GE-179 emission scan
data were available for nine healthy participants without
history of neurological or psychiatric illness and 11 par-
ticipants with focal epilepsy [2, 6].
Ninety-minute dynamic emission images were ac-
quired using a Siemens/CTI ECAT EXACT HR+
(“962”) camera (Knoxville, TN, USA [7]) in 3D mode.
Each participant had been injected with a smooth bolus
intravenous injection of mean ± standard deviation 187
± 4 MBq [18F]GE-179, at 30 s after image acquisition
commenced. A rotating 68Ge rod source was used to
acquire 10-min transmission scans for attenuation and
scatter correction, prior to the dynamic emission scans.
Continuous arterial blood sampling (5 ml/minute) was
performed from 0 to 15 min, and a total of nine
discrete arterial blood samples were taken between
baseline and 90.5 min post-injection.
MRI and PET image pre-processing
An 83-region grey-matter-only ROI map was produced for
each participant using multi-atlas propagation with enhanced
registration (MAPER) [8]. MAPER is an automated anatom-
ical segmentation method that involves co-registering the
participant’s T1-weighted magnetic resonance image (MRI)
to that of 30 healthy controls that have already been manu-
ally labelled (the atlases). This yields individual anatomical
segmentations that are fused via vote-rule decision [9] to
produce the ROI map (see Additional file 1: Figure S2).
PET data pre-processing and the generation of parent
plasma input functions were performed as previously
described [2, 6]. Emission data had been reconstructed
using Fourier rebinning (FORE [10]) and 2D-filtered
backprojection (FBP; ramp filter kernel 2.0 mm full
width at half maximum).
The fraction of plasma radioactivity attributable to the
parent [18F]GE-179 had been fitted to a sigmoid function
normalised to unity at 0 min using CLICKFIT in-house
software version 1.7 (Hinz R, Cunningham VJ, Imaging
Research Solutions Limited, London, UK) running in
MATLAB 2014a (The MathWorks, Natick, MA, USA.).
The original, continuous parent plasma input functions
(ppIFs) were derived as follows [11]: (1) cross-calibration of
continuous and discrete whole blood radioactivity concen-
trations, (2) multiplication of the cross-calibrated continu-
ous (0–15 min) whole blood radioactivity concentrations by
the plasma-over-whole-blood ratio, (3) spline interpolation
of the continuous (0–15 min) plasma radioactivity concen-
trations curve over the additional discrete measurements,
and (4) multiplication of the continuous (0–90 min) plasma
radioactivity curve by the parent fraction.
Voxelwise SA
Voxelwise “classic” SA [12] was performed using
Piwave 8.0 [13], using time constants of 5 s (fast
boundary = 0.2 s−1) and 5100 s (slow boundary =
0.000196 s−1). We confirmed the suitability of
“classic” voxelwise SA by demonstrating that the re-
sultant original ppIF-derived VTs were strongly corre-
lated with original ppIF-derived VTs derived from
compartmental modelling (Additional file 1).
Voxelwise SUVs
SUV images (see [11]) were calculated for all 10-min
epochs from 20–30 to 80–90 min from decay-corrected
summation images, using MICKPM (version 5.4 software,
running in MATLAB (The MathWorks Inc., Cambridge,
UK)). “MICKPM” (Modelling, Input functions and Com-
partmental Kinetics—Parametric Maps) is a quantitative
PET analysis software that is available on request from
Rainer Hinz (Wolfson Molecular Imaging Centre,
University of Manchester; rainer.hinz@manchester.ac.uk).
Epochs of 30–60 and 60–90 min were also tested, but
yielded very similar results (data not shown).
PBIFs
The generation of PBIFs can be split into “magnitude
normalisation” and “scaling” stages, described below.
After controlling for weight and injected dose, we iden-
tified a near-significant (p = 0.08) negative (r = − 0.66) cor-
relation between age and area under the parent fraction
curve. We therefore incorporated this additional variable
into the method used to generate the “magnitude normal-
ised” input functions: (1) normalisation of participants’
ppIFs according to weight, then injected dose, then age
(multiplying each participant’s ppIF according to the ratio
[median value/participant value]); (2) alignment of each
ppIF peak to peak at 80 s; and (3) calculation of the me-
dian (i.e. standardised) ppIF from the 19 ppIFs.
In order to generate individualised PBIFs, the median
ppIF was scaled as follows: (1) linear regression of the
area under the 19 other participants’ ppIF curves (AUCs)
with the parent radioactivity concentration in plasma at
90 min post-injection (assumed equivalent to venous
plasma [14]) and then (2) scaling of the median ppIF ac-
cording to the ratio of the AUC predicted (according to
the linear regression) by the parent radioactivity concen-
tration in the participant’s arterial plasma at 90 min to
the AUC of the median ppIF.
Our PBIF method depended on a single parent plasma
sample. Other approaches to scaling, i.e. according to
injected dose and/or body mass (kg) alone or in combin-
ation, were found to yield weaker correlations with
original ppIF-derived VTs (data not shown).
The PBIFs were used to perform voxelwise SA, as above.
Scan shortening
Voxelwise SA was performed using the original ppIFs
and dynamic emission data over t = 0–60, t = 0–70 min,
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and t = 0–80 min, using slow component boundaries of
0.000290, 0.000256, and 0.000222 s−1, respectively.
Statistical analyses
We calculated the mean (original ppIF derived or PBIF
derived, as applicable) VT/SUV within seven cortical and
subcortical bilateral ROIs using Analyze 7.0 (AnalyzeDirect
Inc., Kansas, USA): cerebelli, hippocampi, occipital lobes,
occipito-temporal (fusiform) gyri, parahippocampal gyri,
putamina, superior frontal gyri (SFG), and thalami. Corre-
lations were interrogated using Spearman’s rank coefficient.
Pooled correlations were quantified using 140 data points
(20 participants × seven ROIs) per variable. Original
ppIF-derived and PBIF-derived VTs, and separately original
ppIF-derived VTs that were calculated using 90- or 60-min
datasets, were compared using Bland–Altman plots. Bind-
ing estimates were compared between subgroups [6]
(epilepsy not on antidepressants, epilepsy on antidepres-
sants, controls) by multivariate analysis of variance, with
age as a covariate; a significant effect (p = 0.007 overall;
individual ROIs p < 0.001) of subgroup on original
ppIF-derived 90-min VTs was already reported [6].
Results
Voxelwise SUVs
SUVs were correlated with 90-min original ppIF-derived
VTs derived from SA (seven ROIs pooled: increasing
with time and reaching a maximum of ρ = 0.78 for
80–90 min; all p < 0.001; Fig. 1; Additional file 1).
The ranges of ρ were 0.34 (SFG) to 0.60 (cerebelli) for
the interval 10–20 min, and 0.65 (hippocampi) to 0.79
(cerebelli and occipital lobes; all p ≤ 0.001) for the inter-
val 80–90 min.
There was very little difference (< 1.3 percentage
points) in the ROI between-subject coefficients of vari-
ation (BS-CVs) between the 80–90 min SUVs and the
original ppIF-derived VTs (Additional file 1: Table S1).
Larger differences were seen using earlier intervals.
The influence of subgroup on original ppIF-derived VT
[6] was not replicated for SUV data (p ≥ 0.05 for each
interval).
PBIFs
PBIF-derived VTs were correlated with VTs calculated
using the participants’ original ppIFs (seven ROIs
pooled ρ = 0.90, p < 0.001). A small bias toward over-
estimation of PBIF-derived VT was observed (linear
regression y = 1.02x − 0.20; see Fig. 2) with a large
variability (mean overestimate 0.7% ± 13.4%).
The range of ρ was 0.81 (hippocampi and occipital
lobes) to 0.92 (cerebelli; all p < 0.001; see Additional file 1:
Table S2). The absolute percent difference between
PBIF-derived VTs and those calculated using the partici-
pants’ original ppIFs varied somewhat unpredictably
across ROIs (Fig. 2), but was worse for elderly, healthy
control participants.
An increase in BS-CV was observed that ranged from
2.5 percentage points (SFG) to 4.1 percentage points
(occipital lobes; see Additional file 1: Table S2), i.e.
mean ± standard deviation BS-CV was 26 ± 2% com-
pared to 23 ± 2% for original ppIF-derived VTs.
The influence of subgroup on original ppIF-derived VT
[6] was not replicated for PBIF-derived VTs (p = 0.11).
Scan shortening
ROI original ppIF-derived VTs calculated using 60-, 70-,
and 80-min datasets were positively correlated with
Fig. 1 Spearman’s rank correlation coefficient versus the midpoint of the SUV interval. The correlation coefficient refers to SUV versus original
ppIF-derived VT for seven ROIs pooled. Error bars indicate 95% confidence intervals
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Fig. 2 Bland–Altman plot for VT calculated using PBIFs versus using the original ppIFs. VTs were calculated using 90-min datasets. The colour scale
depicts ROI (a, top) or participant identification (b, bottom). The dash ovals identify participants with large differences in VT, with their
age in years (the median age of participants was 35 years, interquartile range 26–50 years, range 20–62 years). antid., on antidepressants
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original ppIF-derived VTs derived from the full 90-min
dataset (seven ROIs pooled ρ = 0.98, ρ = 0.99, and ρ =
1.00 respectively; all p < 0.001; Table 1, Fig. 3).
Correlation coefficients ranged from 0.97 (SFG and
thalami, 60 min) to 1.00 (multiple ROIs and scan dura-
tions; all p < 0.001). The original ppIF-derived VT was
increasingly underestimated (relative to original
ppIF-derived VTs calculated using 90-min datasets)
with scan shortening, particularly for medial temporal
lobe ROIs (Table 1, Fig. 4).
There was very little difference (< 0.9 percentage
points) in ROI BS-CVs between the shortened ori-
ginal ppIF-derived VTs and the original ppIF-derived
90-min VTs.
The influence of subgroup on original ppIF-derived
VT [6] was replicated using all shortened datasets:
60 min (p = 0.001), 70 min (p = 0.003), and 80 min
(p = 0.005).
Discussion
We report further analyses of [18F]GE-179 PET datasets
to facilitate wider use of the radiotracer. Our major find-
ings are (1) SUVs were correlated with 90-min original
ppIF-derived VTs; (2) PBIF-derived VTs were more
strongly correlated with original ppIF-derived VT
estimates but had increased BS-CV; (3) original
ppIF-derived VTs calculated over 60+min were very
strongly correlated with 90-min original ppIF-derived
VTs, but with negative bias; and (4) we were able to rep-
licate our original findings using the original
ppIF-derived VTs derived from shortened datasets, but
not using SUVs or PBIF-derived VTs.
While SUVs were only moderately correlated with
original ppIF-derived VTs, the correlation coefficients
started to plateau over later intervals, i.e. from 50 to
60 min onwards (see Fig. 1 and Additional file 1:
Table S1). Our data suggest any increase in correlation
Table 1 Original ppIF-derived VT calculated over various intervals versus original ppIF-derived VT calculated using the 90-min
datasets, via voxelwise SA
0–60 min 0–70 min 0–80 min 0–90 min
Mean ± SD ρ % Mean ± SD ρ % Mean ± SD ρ % Mean ± SD
Cerebelli 9.3 ± 2.4 1.00 − 6.7 9.6 ± 2.5 1.00 − 4.4 9.8 ± 2.5 1.00 − 2.2 10.0 ± 2.5
Hippocampi 9.6 ± 1.8 0.98 − 14.1 10.2 ± 2.0 0.99 − 9.0 10.8 ± 2.1 1.00 − 3.9 11.2 ± 2.2
Occipital lobes 9.9 ± 2.4 0.98 − 8.3 10.2 ± 2.5 0.98 − 5.1 10.5 ± 2.5 1.00 − 2.4 10.7 ± 2.5
Parahippocampal gyri 8.5 ± 2.0 0.98 − 13.8 9.0 ± 2.1 0.99 − 8.8 9.5 ± 2.2 0.99 − 4.1 9.9 ± 2.3
Putamina 11.7 ± 2.6 0.99 − 7.3 12.1 ± 2.7 1.00 − 4.7 12.4 ± 2.8 1.00 − 2.2 12.7 ± 2.9
Superior frontal gyri 9.4 ± 2.2 0.97 − 8.2 9.7 ± 2.3 0.98 − 5.5 10.0 ± 2.3 0.99 − 2.7 10.3 ± 2.3
Thalami 11.4 ± 2.4 0.97 − 10.1 11.9 ± 2.6 0.98 − 6.2 12.3 ± 2.6 0.99 − 2.9 12.7 ± 2.7
Seven pooled ROIs 10.0 ± 2.5 0.98 CI
(0.97–0.99)
− 9.8 10.4 ± 2.6 0.99 CI
(0.98–0.99)
− 6.2 10.7 ± 2.6 1.00 CI
(1.00–1.00)
− 2.9 11.1 ± 2.7
% mean percentage difference, relative to 90-min SA original ppIF-derived VT; ρ Spearman’s rank correlation coefficient; CI 95% confidence interval;
SD standard deviation
Fig. 3 Original ppIF-derived VT images calculated using 60-min (left panel) and 90-min (right panel) datasets. Colour scale—original ppIF-derived
VT; top row—participant with epilepsy on antidepressants (epilepsy—antid. 2); middle row—control participant (control 2); bottom row—participant
with epilepsy, not on antidepressants (epilepsy 5). Images are shown in radiological orientation
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Fig. 4 Bland–Altman plot for 60 min’ original ppIF-derived VT versus 90 min’ original ppIF-derived VT. The colour scale depicts ROI (a, top) or participant
identification (b, bottom). antid., antidepressants; mins, minutes
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coefficient achieved by delaying SUVs to scanning inter-
vals beyond 90 min is likely to be modest.
PBIFs, whether scaled by injected dose, body mass,
whole-blood, or plasma radioactivity, performed some-
what unpredictably across ROIs and inconsistently
across participants. Although normalisation by age is not
a standard approach, in practice, it had a small effect on
the standardised ppIF (median difference ~ 5.5%; data
not shown) which for example translated into a 0.8% dif-
ference in global PBIF-derived [18F]GE-179 VT. Hence,
we do not believe the age normalisation procedure had a
strong bearing on the results.
Where arterial blood sampling is not available, calcula-
tion of SUVs constitutes a convenient alternative with
fewer outliers than the PBIF methods. However, we were
unable to replicate our original finding of differences
between subgroups using SUVs.
We deliberately employed a simple PBIF method that
could be widely implemented. A novel method was re-
cently described that allows simultaneous estimation of
the kinetic rate constants and the input function param-
eters from emission data alone [15]. However, it requires
a priori specification of the number of tissue compart-
ments and can yield a similar margin of error to what
we found for PBIFs [15].
It was not possible to test image-derived input functions
with our data which had a limited field of view. We also
could not test PBIFs anchored via venous blood samples.
Our findings suggest that where arterial blood sampling
is available, it is possible to shorten the scan to 60, 70, or
80 min, without adversely affecting BS-CV or study power.
However, investigators should be aware of the negative bias,
which is more pronounced in the medial temporal lobe.
Additional file
Additional file 1: Voxelwise spectral analysis (SA) versus the two-tissue
compartment model (2c4kbv), voxelwise SUVs calculated overall various
intervals, and PBIF-derived VTs. (PDF 1382 kb)
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